TAILOR-PCI: Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Intervention Save

Date Added
April 9th, 2015
PRO Number
Pro00042372
Researcher
Josh Doll
Keywords
Heart
Summary

The TAILOR-PCI study is a prospective randomized trial to test the hypothesis that after PCI, ticagrelor 90 mg twice a day is superior to clopidogrel 75 mg qd in reducing a composite endpoint of major adverse cardiac events (MACE). The subjects will be randomized to 1 of 2 arms: 1) conventional therapy with retrospective DNA analysis at 12 months post procedure; or 2) prospective genotyping arm.

Institution
Greenville
Recruitment Contact
Grace Jones
864-455-7793
gjones4@ghs.org

Change_preferences

-- OR --

Create_login